![Emily Bates PhD](https://profiles-cardiff.imgix.net/attachments/7548?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Emily Bates
(she/her)
PhD
- Available for postgraduate supervision
Teams and roles for Emily Bates
The Brain Tumour Charity Future Leaders Post-doctoral Fellow
Overview
🔬 I am a research fellow at Cardiff University's VITAL lab, where I completed my PhD in 2022, focusing on modified adenoviral therapies for glioblastoma. Following my PhD, I was funded by Cancer Research Wales which enabled me to explore applications of adenoviral therapies in brain cancer. I am delighted to have been awarded the Brain Tumour Charity Future Leaders Fellowship, in 2024, focusing on developing new adenoviral therapies for patients with the most common form of adult brain cancer, glioblastoma 🧠
Publication
2023
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
2022
- Bates, E. 2022. Developing Species D adenovirus vectors for cancer applications. PhD Thesis, Cardiff University.
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
2021
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
2020
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
Articles
- Mundy, R. M. et al. 2023. Broad sialic acid usage amongst species D human adenovirus. npj Viruses 1, article number: 1. (10.1038/s44298-023-00001-5)
- Bates, E. A., Lovatt, C., Plein, A. R., Davies, J. A., Siebzehnrubl, F. A. and Parker, A. L. 2023. Engineering adenoviral vectors with improved GBM selectivity. Viruses 15(5), article number: 1086. (10.3390/v15051086)
- Bates, E. A. et al. 2022. Development of a low seroprevalence, αvβ6 integrin selective virotherapy based on human adenovirus type 10. Molecular Therapy - Oncolytics 25, pp. 43-56. (10.1016/j.omto.2022.03.007)
- Baker, A. T. et al. 2021. ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. Science Advances 7(49), article number: eabl8213. (10.1126/sciadv.abl8213)
- Bates, E. A. et al. 2021. In vitro and in vivo evaluation of human adenovirus type 49 as a vector for therapeutic applications. Viruses 13(8), article number: 1483. (10.3390/v13081483)
- Baker, A. T. et al. 2021. The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism. Journal of Virology 95(4), article number: e01849-20. (10.1128/JVI.01849-20)
- Hulin-Curtis, S. et al. 2020. Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications. Cancer Gene Therapy 27, pp. 785-798. (10.1038/s41417-019-0156-0)
- Cunliffe, T. G., Bates, E. A. and Parker, A. L. 2020. Hitting the target but missing the point: recent progress towards adenovirus-based precision virotherapies. Cancers 12(11), article number: 3327. (10.3390/cancers12113327)
Thesis
- Bates, E. 2022. Developing Species D adenovirus vectors for cancer applications. PhD Thesis, Cardiff University.
Biography
Dr. Emily Bates is a Brain Tumour Charity Future Leaders Fellow at Cardiff University, focusing on developing novel adenoviral therapies for glioblastoma. She completed her PhD in 2022, investigating oncolytic adenoviral vectors for cancer applications. Dr. Bates has eight peer-reviewed publications (four first author) and is named on two patent applications. She has been awarded PGR Excellence in Innovation, Peter Tomasec Poster Prize, and the ELRIG Early Career Professional Impact Award.
Dr. Bates gained expertise in oncolytic virotherapy during her master’s at MedImmune, whilst studying at the University of Liverpool. Participation in the Innovate UK, ICURe Explore Programme, reflects her commitment to translating academic research into patient treatments. Dr. Bates has presented her work at key conferences and has built collaborations developing a strong research network both locally, in Cardiff, as well as internationally. Dr. Bates also participates in public engagement events to promote cancer research across Wales.
Contact Details
Cancer Genetics Building, University Hospital of Wales, Heath Park, Cardiff, CF14 4XN
Research themes
Specialisms
- Cancer therapy
- Virology